Journal Article

Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia

Plat, Francis, Lubkov, Veronica, Shardonofsky, Silvia, Stambler, Bruce S., Sager, Philip T., Chen, Michael, Wight, Douglas, Camm, A. John

2022

Overview

Presently, acute pharmacological termination of paroxysmal supraventricular tachycardia (PSVT) unresponsive to patient-initiated vagal maneuvers requires in-hospital intervention. Etripamil, a fast-acting, nondihydropyridine, L-type calcium channel blocker, is formulated as an intranasal spray to rapidly terminate atrioventricular (AV) nodal-dependent PSVT in a medically unsupervised setting. The NODE-301 study did not meet its prespecified primary end point of PSVT conversion over 5 hours following a single dose of etripamil 70 mg. However, analysis at earlier time points demonstrated etripamil treatment effect during the first 30 minutes, consistent with its expected rapid onset and short duration of action. This led to the design of the RAPID study, which includes a new dosing regimen (up to 2 etripamil 70 mg doses separated by 10 minutes) to increase the exposure and pharmacodynamic effect of etripamil. The primary objective of RAPID (NCT03464019) is to determine if etripamil self-administered by patients is superior to placebo in terminating PSVT in an at-home setting. The secondary objective is to evaluate the safety of etripamil when self-administered by patients without medical supervision. Additional efficacy end points include the proportion of patients requiring additional medical intervention in an emergency department to terminate PSVT and patient-reported outcomes. After successfully completing a test dose to assess the safety of 2 70 mg doses of etripamil during sinus rhythm, approximately 500 patients will be randomized 1:1 to etripamil or placebo to accrue 180 positively adjudicated AV nodal-dependent PSVT events for treatment with the study drug. Etripamil may offer a new alternative to the current in-hospital treatment modality, providing for safe and effective at-home termination of PSVT.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Adenosine / Arrhythmia termination / Atrioventricular nodal reentrant tachycardia / Atrioventricular reentrant tachycardia / Benzoates - therapeutic use / Calcium channel blocker / Calcium channel blockers / Calcium channels / Calcium channels (L-type) / Cardiac arrhythmia / Clinical Trials, Phase III as Topic / Conversion / Dosage / Drug dosages / Effectiveness / Electrocardiography / Emergency medical care / Emergency medical services / Etripamil / Humans / Intranasal / Multicenter Studies as Topic / Paroxysmal supraventricular tachycardia / Patients / Pharmacodynamics / Pharmacology / Placebos / Randomized Controlled Trials as Topic / Safety / Sinuses / Tachycardia / Tachycardia, Paroxysmal - drug therapy / Tachycardia, Supraventricular / Tachycardia, Ventricular / Vagus nerve